ICU Medical/$ICUI
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About ICU Medical
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.
Ticker
$ICUI
Sector
Primary listing
Employees
15,000
Headquarters
Website
ICU Medical Metrics
BasicAdvanced
$3B
-
-$1.51
0.86
-
Price and volume
Market cap
$3B
Beta
0.86
52-week high
$177.63
52-week low
$107.00
Average daily volume
235K
Financial strength
Current ratio
2.444
Quick ratio
0.993
Long term debt to equity
63.226
Total debt to equity
66.404
Interest coverage (TTM)
1.21%
Profitability
EBITDA (TTM)
331.339
Gross margin (TTM)
35.84%
Net profit margin (TTM)
-1.56%
Operating margin (TTM)
5.21%
Effective tax rate (TTM)
332.40%
Revenue per employee (TTM)
$160,000
Management effectiveness
Return on assets (TTM)
1.84%
Return on equity (TTM)
-1.78%
Valuation
Price to revenue (TTM)
1.242
Price to book
1.4
Price to tangible book (TTM)
-35.23
Price to free cash flow (TTM)
58.339
Free cash flow yield (TTM)
1.71%
Free cash flow per share (TTM)
2.058
Growth
Revenue change (TTM)
2.96%
Earnings per share change (TTM)
-48.47%
3-year revenue growth (CAGR)
10.04%
10-year revenue growth (CAGR)
22.15%
3-year earnings per share growth (CAGR)
83.86%
10-year earnings per share growth (CAGR)
-4.16%
What the Analysts think about ICU Medical
Analyst ratings (Buy, Hold, Sell) for ICU Medical stock.
Bulls say / Bears say
ICU Medical’s GAAP gross margin expanded to 38% in Q2 2025, up from 35% a year earlier, driving a swing to GAAP net income of $35.3 million versus a net loss of $21.4 million, reflecting improved operating leverage and cost controls. (GlobeNewswire)
The deconsolidation of the IV Solutions business, after the May 1, 2025 joint venture, added 300 basis points to gross margin, with SEC filings showing Q2 2025 gross margin rising to 37.9% from 34.8% in Q2 2024. (SEC EDGAR)
Revenue from the Consumables segment rose 9.1% year-over-year to $266.2 million in Q1 2025, driven by higher prices and increased market share in oncology and home infusion, highlighting the strength of ICU Medical’s main business. (GlobeNewswire)
ICU Medical’s total revenue dropped 8.0% year-over-year in Q2 2025 to $548.9 million, pressured by the transfer of IV Solutions sales to the joint venture and weaker demand in the Vital Care segment. (GlobeNewswire)
The company expects $25 million to $30 million in additional tariff costs for FY 2025, including a 15% tariff on imports from Costa Rica, which could impact margins and earnings. (Investing.com)
Vital Care segment revenue declined due to the sale of a controlling interest in the IV Solutions business, with SEC filings reporting a significant decrease in this lower-margin line of business in Q2 2025. (SEC EDGAR)
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2025.
ICU Medical Financial Performance
Revenues and expenses
ICU Medical Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ICU Medical stock?
ICU Medical (ICUI) has a market cap of $3B as of November 04, 2025.
What is the P/E ratio for ICU Medical stock?
The price to earnings (P/E) ratio for ICU Medical (ICUI) stock is 0 as of November 04, 2025.
Does ICU Medical stock pay dividends?
No, ICU Medical (ICUI) stock does not pay dividends to its shareholders as of November 04, 2025.
When is the next ICU Medical dividend payment date?
ICU Medical (ICUI) stock does not pay dividends to its shareholders.
What is the beta indicator for ICU Medical?
ICU Medical (ICUI) has a beta rating of 0.86. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.